• SGC-CBP30: Testing Super-Enhancer Dependency

  2026-08-15

  SGC-CBP30 is a selective CREBBP/EP300 bromodomain inhibitor for dissecting transcriptional coactivator dependence in epigenetics research. This article translates lung adenocarcinoma findings into a rigorous, tiered assay strategy while clarifying what bromodomain inhibition can—and cannot—prove.

• CA-074 Me for Lysosomal Cathepsin B Studies

  2026-08-14

  CA-074 Me provides a cell-permeable way to test whether cathepsin B activity links lysosomal membrane permeabilization to regulated cell death. This workflow-oriented guide covers dosing, live-cell imaging, apoptosis assay design, selectivity controls, and translation to TNF-α-driven inflammation research.

• Biotin-16-UTP: Designing RNA–Protein Assays

  2026-08-14

  Biotin-16-UTP enables controlled biotin-labeled RNA production for capture, detection, and interaction experiments. This guide connects reagent design to endogenous protein imaging, showing how orthogonal assays can separate RNA binding from native protein localization.

• Cisplatin (CDDP): Reading Resistance Mechanisms

  2026-08-13

  Cisplatin and CDDP remain powerful tools for cancer research, but resistance analysis requires more than a viability endpoint. This article translates recent ferroptosis findings into practical apoptosis assay, chemoresistance, and translational study decisions.

• LY364947: TGF-β Type I Kinase Inhibitor

  2026-08-13

  LY364947 is a selective TGF-β type I receptor kinase inhibitor for preclinical studies of Smad2 phosphorylation, epithelial-mesenchymal transition (EMT), fibrosis, and retinal injury. Product information describes pathway inhibition, EMT-marker changes, and DMSO-based handling requirements, while independent pancreatic cancer research provides contextual evidence for TGF-β/Smad pathway crosstalk rather than direct validation of LY364947.

• OTUD3, SLC7A11, and Sunitinib Resistance in ccRCC

  2026-08-12

  The reference study identifies OTUD3-mediated deubiquitination of SLC7A11 as a mechanism that preserves cystine uptake, limits oxidative stress, and suppresses sunitinib-induced ferroptosis in clear cell renal cell carcinoma. Its findings connect protein stability control with lipid peroxide biology and suggest that OTUD3 may be investigated as a way to restore drug sensitivity, although clinical validation remains necessary.

• Flubendazole: Autophagy Research Guide

  2026-08-12

  Flubendazole is a benzimidazole-derived autophagy activator for controlled laboratory studies of cellular degradation and signaling. Its defined composition, DMSO compatibility, and research-only status support assay planning, while liver-fibrosis findings on glutamine metabolism should not be interpreted as direct evidence for Flubendazole efficacy.

• PEI MW 40,000 for Cuproptosis Assays

  2026-08-11

  Polyethylenimine Linear (PEI), MW 40,000 provides a scalable route for DNA delivery when studying AC008406.3, docetaxel response, and cuproptosis. This article connects PEI transfection chemistry with assay design, controls, and interpretation rather than treating transfection efficiency as the only endpoint.

• From Surface Tags to Synaptic Mechanism

  2026-08-11

  A translational framework for using Sulfo-NHS-SS-Biotin to connect neuronal receptor surface expression with calcium signaling, affinity workflows, and mechanistic decision-making.

• ROS-Degradable LNPs for Tumor-Selective mRNA

  2026-08-10

  The reference study developed a combinatorial library of thioketal-containing, ROS-degradable lipids and identified BAmP-TK-12 as a preferential mRNA carrier for tumor cells. Delivery of DUF5 mRNA enabled mutant RAS depletion and produced stronger antitumor effects than a small-molecule RAS inhibitor in the reported models, while also highlighting important limits in selectivity, biodistribution, and translational validation.

• AG-490 Workflow for JAK2/STAT6 Signaling Studies

  2026-08-09

  AG-490 (Tyrphostin B42) provides a reversible pharmacological approach for testing how exosomal SNORD52 influences JAK2/STAT6 activity and macrophage polarization. This workflow combines pathway-resolved phosphoprotein analysis with exosome and viability controls, helping distinguish on-target signaling effects from multi-kinase or cytotoxic artifacts.

• ClpP Activation and Cell-Cycle Arrest in Lung Cancer

  2026-08-08

  The reference study identifies ZK53 as a selective activator of human mitochondrial ClpP and shows that mitochondrial proteostasis disruption can suppress lung squamous cell carcinoma. Its integrated structural, cellular, and in vivo evidence connects ClpP hyperactivation with impaired oxidative phosphorylation, ATM-mediated DNA damage response signaling, and cell-cycle arrest.

• E-64: From Cathepsin Inhibition to Assay Insight

  2026-08-07

  E-64 is an irreversible L-trans-epoxysuccinyl peptide for cysteine protease inhibition. This article explains how a phenotype-negative renal study improves experimental design, target-engagement analysis, and interpretation of cathepsin assays.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit: Evidence &

  2026-08-07

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit enables efficient, customizable fluorescent RNA probe synthesis for in situ hybridization and Northern blotting. This Cy3 RNA labeling kit balances high transcription yields with controlled Cy3-UTP incorporation, supporting reproducible detection of RNA targets in research applications. Rigorous evidence and workflow parameters are provided for optimal experimental performance.

• SM-102: High-Purity Lipid for mRNA Delivery and Vaccine Syst

  2026-08-06

  SM-102, a synthetic lipid (heptadecan-9-yl 8-((2-hydroxyethyl)(6-oxo-6-(undecyloxy)hexyl)amino)octanoate), enables efficient mRNA vaccine delivery as a critical lipid nanoparticle component. Its high purity and evidence-backed role in endosomal escape underpin its growing application in mRNA-based therapies.

554 records 8/37 page Previous Next First page 上5页 678910 下5页 Last page